The United States market has remained flat over the past week but has shown an 8.5% increase over the past year, with earnings expected to grow by 14% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability in capturing emerging opportunities within this dynamic sector.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 20.44% | 29.79% | ★★★★★★ |
| TG Therapeutics | 26.18% | 37.61% | ★★★★★★ |
| Alkami Technology | 20.02% | 85.16% | ★★★★★★ |
| Travere Therapeutics | 28.43% | 65.01% | ★★★★★★ |
| AVITA Medical | 27.91% | 55.77% | ★★★★★★ |
| TKO Group Holdings | 22.48% | 25.17% | ★★★★★★ |
| Clene | 60.86% | 63.07% | ★★★★★★ |
| Alnylam Pharmaceuticals | 22.76% | 58.40% | ★★★★★★ |
| Lumentum Holdings | 21.55% | 119.67% | ★★★★★★ |
| Ascendis Pharma | 32.36% | 59.79% | ★★★★★★ |
Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.
Let's dive into some prime choices out of from the screener.
Gilead Sciences (NasdaqGS:GILD)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for unmet medical needs globally with a market cap of $134.36 billion.
Operations: Gilead generates revenue primarily from the discovery, development, and commercialization of innovative medicines, amounting to $28.75 billion. The company operates in the United States, Europe, and internationally.
Gilead Sciences has demonstrated resilience and innovation, particularly in its HIV treatment and prevention segments. With a recent executive change, appointing Diane E. Wilfong as interim Corporate Controller, the company remains stable in leadership transitions. At the Conference on Retroviruses and Opportunistic Infections (CROI 2025), Gilead presented promising data from its ALLIANCE trial showing Biktarvy's efficacy in HIV/HBV co-infection with high virologic suppression rates of 95.4% for HIV-1. Additionally, lenacapavir continues to show potential as a long-acting PrEP solution with ongoing Phase 1 studies indicating effective plasma concentrations for over a year post-administration, reinforcing Gilead's commitment to addressing global health challenges through groundbreaking R&D efforts focused on multi-stage mechanisms of action in antiviral treatments.
- Get an in-depth perspective on Gilead Sciences' performance by reading our health report here.
Gain insights into Gilead Sciences' past trends and performance with our Past report.
nCino (NasdaqGS:NCNO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: nCino, Inc. is a software-as-a-service company that offers cloud-based software applications to financial institutions worldwide, with a market capitalization of approximately $3.40 billion.
Operations: nCino generates revenue primarily from its software and programming segment, amounting to $522.98 million. The company focuses on delivering cloud-based solutions tailored for financial institutions both in the U.S. and internationally.
nCino, poised for significant growth with a projected revenue increase of 13.3% annually, outpaces the U.S. market forecast of 8.5%. This fintech firm is on track to profitability within three years, reflecting an impressive expected earnings surge of 126.78% per year. Recent strategic board enhancements and executive shifts underscore its commitment to robust governance and innovation in financial software solutions, marking nCino as a dynamic contender in the high-growth tech landscape despite current unprofitability challenges.
- Click to explore a detailed breakdown of our findings in nCino's health report.
Understand nCino's track record by examining our Past report.
Fair Isaac (NYSE:FICO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Fair Isaac Corporation specializes in developing software that utilizes analytics and digital decisioning technologies to help businesses automate and improve decision-making processes across various regions, with a market cap of $46.87 billion.
Operations: The company generates revenue primarily from two segments: Scores, contributing $963.21 million, and Software, contributing $812.22 million.
Fair Isaac, known for its FICO scores, is making strategic moves that underscore its adaptability and foresight in the financial technology landscape. Recently, Fair Isaac announced a significant partnership with Fujitsu to expand its offerings into Japan, aiming to enhance digital transformation in the financial sector starting July 2025. This collaboration is set to leverage Fujitsu's deep market penetration and technological prowess to introduce FICO's advanced decisioning tools across various financial platforms. Additionally, Fair Isaac's recent earnings report showcased a robust performance with first-quarter revenue rising from $382.06 million to $439.97 million year-over-year and net income increasing significantly from $121.07 million to $152.53 million. These figures not only reflect solid growth but also highlight Fair Isaac’s capacity for maintaining momentum in innovation and market expansion.
Seize The Opportunity
- Discover the full array of 235 US High Growth Tech and AI Stocks right here.
- Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
- Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Gilead Sciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com